The National Medical Insurance Administration released a list of the second batch of institutions that negotiated drug allocation, involving 92 drugs, which were deployed in 84,000 designated medical institutions across the country

  92 newly negotiated drugs are equipped with 84,000 designated medical institutions

  Yesterday, the National Medical Insurance Administration released a list of institutions that negotiated drug allocation (the second batch), involving 92 drugs, all of which were newly negotiated to enter the national medical insurance list in 2020.

  As of the end of May this year, 92 medicines were deployed in 84,000 designated medical institutions across the country, including 32,000 designated medical institutions and 52,000 designated retail pharmacies.

  Beijing News Yesterday, the National Medical Insurance Administration held a press conference to introduce the release of the second batch of negotiated drug allocation agencies.

  73 medicines cover more than 20 provinces

  In April this year, the National Medical Insurance Administration announced the first batch of negotiated drug allocation institutions, involving 19 drugs such as carrelizumab for injection.

As of April 15th, 19 negotiated medicines are available in 3,324 designated medical institutions across the country, of which 1,417 are designated medical institutions and 1,907 are designated retail pharmacies.

  In order to facilitate the timely purchase of drugs under the National Medical Insurance Negotiations for the majority of patients, and to alleviate the "difficulty in landing" the negotiated drugs, the National Medical Insurance Bureau has organized relevant companies to submit a list of institutions for the negotiation of drugs.

The equipment information submitted by the organization this time involved a total of 92 drugs, all of which were newly added to the national medical insurance catalog during the 2020 negotiations.

  As of May 31, 2021, 92 medicines were deployed in 84,000 designated medical institutions across the country, including 32,000 designated medical institutions and 52,000 designated retail pharmacies.

In terms of varieties, 5 medicines including voronola fumarate green tablets are equipped in 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps across the country, and 73 medicines have covered more than 20 provinces.

  Establish an information reporting mechanism for negotiated drug allocation agencies

  Zhang Xifan, Director of the Catalogue Department of the Medical Management Department of the National Medical Insurance Administration, introduced that the National Medical Insurance Administration has recently carried out three major tasks in terms of information submission for negotiating drug allocation agencies.

  One is to establish a reporting mechanism.

Issue notices to relevant companies, and put forward clear requirements on the scope, content format, procedure, time limit, etc. of the drugs to be submitted, so as to consolidate the main responsibility of the company.

Supervise each company to determine a liaison officer who is responsible for submitting information in accordance with procedures.

  The second is to organize enterprises to submit information.

Organize relevant enterprises to report the allocation of 92 negotiated drugs.

Arrange a special person to be responsible for scheduling, formal review and communication and coordination, and notify the company to correct and improve the problem as soon as possible, and strive to ensure that the information is comprehensive, accurate and timely.

  The third is to optimize the query module.

Developed the "medical companies to submit the second batch of National Medical Insurance Negotiation Drug Provisioning Institutions Online" and "Negotiating Drug Provisioning Institutions Reference List Query Module" on the national medical insurance service platform, and set up an access port on the homepage to facilitate patient inquiries.

  In the next step, the Medical Insurance Bureau will continue to expand the scope of negotiated drug submissions, optimize the reporting procedures, improve the regular release mechanism, strengthen guidance and scheduling, and promote the landing of negotiated drugs through continuous update and release of the list of negotiated drug allocation agencies.

  Focus 1

  The number of institutions that urgently need drugs in clinical medicine is growing rapidly

  Zhang Xifan introduced that, in general, there are several characteristics in the negotiation of drug equipment.

The first is that the number of institutions with urgent clinical needs for drugs has maintained rapid growth.

Compared with April, the number of 19 institutions with urgent clinical need for medicines increased from 3324 to 5572, an increase of 68%; the number of provinces covered also continued to increase, with the average number of provinces covered from 22 to 25.

  At the same time, there are differences in the provision of medicines in different treatment fields. The provision of oncology and chronic diseases is better than that of anti-infection, orthopedics, and parenteral nutrition.

  Among the medicines on the market during the same period, the number of Western medicine equipment institutions is higher than that of Chinese patent medicines.

The number of equipped institutions is positively correlated with the time to market for the drug. The longer the time to market, the greater the number of equipped institutions.

  In addition, there are differences between different regions.

In terms of the average number of medicines, the eastern, central and western regions showed a downward trend.

In terms of provinces, Jiangsu and Henan are equipped with the most medicines, covering 89 medicines.

13 provinces such as Beijing cover more than 80 medicines, Hainan, Ningxia and other places cover less than 50 medicines, and Tibet only covers 9 medicines.

  Focus 2

  13 urgently-needed tumor drugs covering 31 provinces across the country

  Shi Yuankai, chairman of the China Cancer Foundation, introduced at the press conference the availability of 13 urgently needed oncology drugs in the medical insurance catalog. These 13 oncology drugs involve non-small cell lung cancer, breast cancer, ovarian cancer, fallopian tube cancer, lymphoma, and leukemia. 12 kinds of tumors.

  It is reported that before May 31, the data of these drug distribution institutions have increased to varying degrees compared with April.

According to Shi Yuankai, these medical institutions and retail pharmacies are located in 31 provinces (autonomous regions and municipalities) across the country, providing a very convenient way for patients everywhere to use these drugs included in the national medical insurance reimbursement catalog in a timely manner.

  Shi Yuankai said that these drugs are the latest drugs in the field of tumor treatment in recent years, involving targeted therapy, immunotherapy and other treatment methods. "After the National Medical Insurance Bureau included these drugs in the catalog, my country's tumor patients received the latest global The best treatment."

  Shi Yuankai further pointed out: "The National Medical Insurance Bureau has clear indications when including these oncology drugs, including what kind of patients can be used in what period of treatment, and it is very clear to ensure the effectiveness and rationality of clinical applications. "

  ■ Sound

  Medical insurance negotiation drugs will be more in place over time

  Shi Luwen, a professor at the School of Pharmacy of Peking University, said that the provision of newly negotiated drugs is a topic of great concern to the public.

"Pharmaceuticals are equipped with market attributes. Although the country negotiates access and is included in the scope of reimbursement, it needs to be guaranteed by the company under the laws of the market. It takes a certain time and process for all drug equipment from enterprise production, circulation and then to medical institutions. If you extend it, it will naturally be equipped more in place."

  The Shilu Wen mentioned that even if the equipment is in place, it must be combined with the characteristics of the corresponding medical institutions, the scope of services, and the characteristics of local diseases.

Some hospitals will not be equipped if they do not have the ability to treat certain diseases.

  At the same time, he also said that companies should actively take on the responsibility of improving the availability of negotiated drugs, and do a good job of guaranteeing the promotion of negotiated drugs in designated institutions within their capabilities.

  Beijing News reporter Wu Wei